Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,300 | 2018-10-23 00:00:00 UTC | 10 Blue-Chip Stocks to Buy for an Earnings Bump | ABBV | https://www.nasdaq.com/articles/10-blue-chip-stocks-buy-earnings-bump-2018-10-23 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's here. We're now entering the thick of earnings season, with more companies scheduled to report their numbers this week than any other week of the quarter. And an already-volatile time of year is made even more volatile this time around as investors sta... | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. I... | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. S... | Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. T... | Decided year-over-year earnings growth is the norm in every quarter, and AbbVie hasn't failed to top a quarterly earnings estimate in years. Source: iStockphoto AbbVie (ABBV) AbbVie (NYSE: ABBV ) has been a little more hit-and-miss following the delivery of quarterly reports of late … and arguably more miss than hit. T... |
25,301 | 2018-10-23 00:00:00 UTC | AbbVie Becomes Oversold (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-becomes-oversold-abbv-2018-10-23 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and ... | The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per share, with $125.86 as the 52 week high point - that compares with a last trade of $82.74. In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold terri... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $81.50 per shar... | In trading on Tuesday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $81.50 per share. A bullish investor could look at ABBV's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and ... |
25,302 | 2018-10-22 00:00:00 UTC | Insiders Now Seeing Red With ABBV At New 52-Week Low | ABBV | https://www.nasdaq.com/articles/insiders-now-seeing-red-abbv-new-52-week-low-2018-10-22 | null | null | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. That's a $42.36 share price drop, or -33.66% decline from the 52-week high of $125.86 set back on 01/26/2018. Large percentage drops always require that the stock post even larger percentage gains from the low in order ... | Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. The chart below shows where ABBV has traded over the past year, with the 50-day and 20... | Time will tell whether the insider purchases foretell a future rebound for ABBV shares, which are presently showing a last trade of $85.20/share, a 2.04% rebound off of the new 52-week low. In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. Large percentage drops always... | Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the 52-week high. So let's take a look to see whether any company insiders were taking the other side of... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) touched a new 52-week low of $83.50/share. Large percentage drops always require that the stock post even larger percentage gains from the low in order to recover the old price point, and for ABBV that means the stock would have to gain 50.73% to get back to the... |
25,303 | 2018-10-21 00:00:00 UTC | 3 Dividend Stocks That Pay You More Than Coca-Cola Does | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-pay-you-more-coca-cola-does-2018-10-21 | null | null | With a better than 50-year history of paying dividends, Coca-Cola (NYSE: KO) is seen as an icon of stable, strong, secure payouts. Yet as consumers move away from soda consumption toward healthier beverages, there will be challenges ahead for its business, which is why it is branching out into new areas, such as its $5... | A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . But AbbVie -- the ... | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the ... | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the ... | Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D) , AbbVie (NYSE: ABBV) , and MGM Growth Properties (NYSE: MGP) . A bargain dividend play George Budwell (AbbVie): Coca-Cola has undoubtedly been an outstanding cash cow for income investors over the years. But AbbVie -- the ... |
25,304 | 2018-10-19 00:00:00 UTC | Noteworthy Friday Option Activity: SBNY, FRPT, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-sbny-frpt-abbv-2018-10-19 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Signature Bank (Symbol: SBNY), where a total volume of 2,215 contracts has been traded thus far today, a contract volume which is representative of approximately 221,500 underlying shares (given that ev... | Particularly high volume was seen for the $89.50 strike put option expiring October 19, 2018 , with 3,054 contracts trading so far today, representing approximately 305,400 underlying shares of ABBV. Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And Ab... | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the ... | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the ... | Below is a chart showing FRPT's trailing twelve month trading history, with the $35 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 21,497 contracts, representing approximately 2.1 million underlying shares or approximately 42.5% of ABBV's average daily trading volume over the ... |
25,305 | 2018-10-17 00:00:00 UTC | EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq | ABBV | https://www.nasdaq.com/articles/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq-2018-10-17 | null | null | EyePoint Pharmaceuticals, Inc.EYPT announced that the FDA has approved Yutiq (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis affecting the posterior section of the eye.
Yutiq is a tiny micro-insert that utilizes EyePoint's Durasert drug delivery technology, containing 0.18 mg f... | AbbVie's ABBV Humira and Allergan's AGN Ozurdex are approved for a similar disease. Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this art... | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are ap... | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are ap... | Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alimera Sciences, Inc. (ALIM): Free Stock Analysis Report pSivida Corp. (EYPT): Get Free Report To read this article on Zacks.com click here. AbbVie's ABBV Humira and Allergan's AGN Ozurdex are ap... |
25,306 | 2018-10-15 00:00:00 UTC | Company News For Oct 15, 2018 | ABBV | https://www.nasdaq.com/articles/company-news-for-oct-15-2018-2018-10-15 | null | null | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million
The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan... | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan... | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan... | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan... | First Republic Bank FRC shares climbed 2.5% after the company reported third quarter 2018 revenues of $768.8 million, beating the Zacks Consensus Estimate of $765.8 million The PNC Financial Services Group Inc. PNC tumbled 5.6% following marginal loan growth in the third quarter and after projecting a slow pace of loan... |
25,307 | 2018-10-15 00:00:00 UTC | 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better | ABBV | https://www.nasdaq.com/articles/2-pharmaceutical-stocks-buy-dividends-3-or-better-2018-10-15 | null | null | During a tough week for the overall market, pharmaceutical stocks across the board fell a few notches despite a lack of significant news for the industry itself. That brought already attractive dividend yields for Pfizer Inc. (NYSE: PFE) and Gilead Sciences Inc. (NASDAQ: GILD) firmly into the 3% range.
A yield above 3%... | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Gilead Sciences Inc.: Turnaround time This drugmaker offers an above-a... | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Pfizer's rheumatoid arthritis tablet, Xeljanz, recently earned approva... | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Pfizer Inc.: Time to shine Over the past five years, Pfizer has been a... | The company's HCV segment fell hard in response to competition from AbbVie 's (NYSE: ABBV) Mavyret, but a bold move could stabilize the franchise. Gilead recently launched generic versions of its own branded treatments priced to compete with AbbVie. Gilead Sciences Inc.: Turnaround time This drugmaker offers an above-a... |
25,308 | 2018-10-12 00:00:00 UTC | Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-abbv-nvs-humira-biosimilar-agreement-bmys-new-cancer-deal-2018-10-12 | null | null | This week was a relatively quiet one for the pharma sector ahead of earnings. In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new on... | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drug... | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drug... | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drug... | In key developments, AbbVie ABBV signed its fourth licensing deal to protect revenues from its blockbuster drug Humira; J&J JNJ gained FDA approval for label expansion of its blood thinner, Xarelto and Bristol Myers Squibb BMY signed a new oncology collaboration with Compugen to study a combination of their cancer drug... |
25,309 | 2018-10-12 00:00:00 UTC | Bristol-Myers Inks Deal and Invests $12 Million in Compugen | ABBV | https://www.nasdaq.com/articles/bristol-myers-inks-deal-and-invests-%2412-million-in-compugen-2018-10-12 | null | null | Bristol-Myers Squibb CompanyBMY announced that it has entered a clinical trial collaboration with Compugen CGEN . Per the deal, the companies will evaluate the safety and tolerability of Compugen's COM701, an investigational antibody, in combination with Bristol-Myers' immune checkpoint inhibitor, Opdivo, in patients w... | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination wi... | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination wi... | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination wi... | Bristol-Myers collaborated with several other research institutes, and small and large biotech and pharma companies, including Johns Hopkins University, Johnson & Johnson JNJ , AbbVie ABBV , Five Prime, Lilly, Celgene, Celldex, Nektar, Infinity Pharma and Seattle Genetics, for the evaluation of Opdivo in combination wi... |
25,310 | 2018-10-12 00:00:00 UTC | AbbVie Settles With Novartis to Delay Humira Biosimilar in US | ABBV | https://www.nasdaq.com/articles/abbvie-settles-with-novartis-to-delay-humira-biosimilar-in-us-2018-10-12 | null | null | AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS , involving AbbVie's blockbuster arthritis drug, Humira (adalimumab). The company has signed a non-exclusive licensing deal with Sandoz related to Novartis' proposed biosimilar version of Humira, in the United State... | The company has signed a non-exclusive licensing deal with Sandoz related to Novartis' proposed biosimilar version of Humira, in the United States, Europe and other countries where AbbVie has intellectual property. AbbVie, Inc.ABBV announced that it has settled a litigation with Sandoz, the generic arm of Novartis NVS ... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis R... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank AbbVie currently has a Zacks Rank #3 (Hold). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis R... | However, AbbVie has successfully struck licensing deals with four companies to protect its revenues from HumiraThis gives AbbVie more time to strengthen its pipeline with products that are capable of making up for the expected sales decline when Humira biosimilars are launched. AbbVie, Inc.ABBV announced that it has se... |
25,311 | 2018-10-12 00:00:00 UTC | 3 Big Pharma Stocks Racing Along the Road to China | ABBV | https://www.nasdaq.com/articles/3-big-pharma-stocks-racing-along-road-china-2018-10-12 | null | null | China has an immense cancer problem, but it's about to get a lot better. The country's National Health Insurance Administration recently added 17 well-known cancer drugs to the list of treatments it's willing to pay for.
In the quarters ahead, a handful of products from Pfizer Inc. (NYSE: PFE) , AstraZeneca PLC (NYSE: ... | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Despite having a highly targeted audience, Tagrisso sales in the U.S. hit an annualized $1.4 billion run rate in the second quarter and could climb much hig... | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of... | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of... | J&J markets Imbruvica outside of the U.S. while AbbVie (NYSE: ABBV) handles commercialization in the U.S. and the pair generally split the profits down the middle. Johnson & Johnson: Imbruvica Since earning FDA approval to treat newly diagnosed patients with the most common form of leukemia, Imbruvica has become one of... |
25,312 | 2018-10-10 00:00:00 UTC | AbbVie (ABBV) Stock Moves -1.54%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-1.54%3A-what-you-should-know-2018-10-10 | null | null | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. This move was narrower than the S&P 500's daily loss of 3.29%. Meanwhile, the Dow lost 3.15%, and the Nasdaq, a tech-heavy index, lost 4.08%.
Prior to today's trading, shares of the drugmaker had gained 1.49% ov... | On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings rel... | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, ABBV is projected to report earnings of $2.01 per share, which w... | AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be November 2, 2018. On that day, ABBV is projected to report earnings of $2.01 per share, which w... | On that day, ABBV is projected to report earnings of $2.01 per share, which would represent year-over-year growth of 42.55%. AbbVie (ABBV) closed the most recent trading day at $93.11, moving -1.54% from the previous trading session. Investors will be hoping for strength from ABBV as it approaches its next earnings rel... |
25,313 | 2018-10-10 00:00:00 UTC | Neurocrine Inks Deal with Private Biotech to Make CNS Drugs | ABBV | https://www.nasdaq.com/articles/neurocrine-inks-deal-with-private-biotech-to-make-cns-drugs-2018-10-10 | null | null | Neurocrine Biosciences, Inc.NBIX announced that it has struck a research collaboration deal with privately held small biotech Jnana Therapeutics to identify novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders. The partnership will leverage Jnana's proprietary drug discovery pla... | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Bioscience... | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Bioscience... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Biosciences, Inc. (NBIX): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report GlycoMimetics, Inc. (GLYC): Free Stock Analysis Report To read this article on Zacks.com click here. In July, th... | In July, the FDA approved Orilissa (elagolix), which Neurocrine developed in partnership with AbbVie ABBV for the treatment of moderate to severe pain associated with endometriosis, a common gynecologic disorder in women. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Neurocrine Bioscience... |
25,314 | 2018-10-10 00:00:00 UTC | J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study | ABBV | https://www.nasdaq.com/articles/jjs-stelara-succeeds-in-phase-iii-ulcerative-colitis-study-2018-10-10 | null | null | Johnson & JohnsonJNJ announced new data from a phase III study, evaluating its drug Stelara in adults with moderate-to-severe ulcerative colitis ("UC"). The eight-week induction data from the pivotal phase III UNIFI study showed that a single intravenous (IV) dose of the medicine induces clinical remission and response... | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free St... | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free St... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Other marketed UC treatments include Pfizer's PFE JAK ... | Other marketed UC treatments include Pfizer's PFE JAK inhibitor, Xeljanz, AbbVie's ABBV Humira and Shire's SHPG Lialda. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Shire plc (SHPG): Free St... |
25,315 | 2018-10-10 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-abbvie-connectone-bancorp-and-pennymac-mortgage-investment-trust-2018 | null | null | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on ... | As a percentage of ABBV's recent stock price of $94.07, this dividend works out to approximately 1.02%, so look for shares of AbbVie Inc to trade 1.02% lower - all else being equal - when ABBV shares open for trading on 10/12/18. If they do continue, the current estimated yields on annualized basis would be 4.08% for A... | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on ... | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $0.96 on ... | Looking at the universe of stocks we cover at Dividend Channel , on 10/12/18, AbbVie Inc (Symbol: ABBV), ConnectOne Bancorp Inc (Symbol: CNOB), and Pennymac Mortgage Investment Trust (Symbol: PMT) will all trade ex-dividend for their respective upcoming dividends. As a percentage of ABBV's recent stock price of $94.07,... |
25,316 | 2018-10-08 00:00:00 UTC | AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis | ABBV | https://www.nasdaq.com/articles/abbvies-orilissa-gets-canadian-nod-to-treat-endometriosis-2018-10-08 | null | null | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. Orilissa was approved in the United States in ... | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. With Orilissa approved to treat pain associate... | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. AbbVie Inc. Price AbbVie Inc. Price | AbbVie I... | AbbVieABBV along with its partner Neurocrine Biosciences, Inc. NBIX announced that Health Canada has approved Orilissa (elagolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of moderate to severe pain associated with endometriosis. AbbVie Inc. Price AbbVie Inc. Price | AbbVie I... | With Orilissa approved to treat pain associated with endometriosis, it can address a market with significant unmet need to bring in more revenues for AbbVie. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently has a Zacks Rank #3 (Hold). AbbVieABBV along with its par... |
25,317 | 2018-10-08 00:00:00 UTC | 3 Top Biotech Stocks to Buy in October | ABBV | https://www.nasdaq.com/articles/3-top-biotech-stocks-buy-october-2018-10-08 | null | null | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher an... | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher an... | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. Too cheap to ignore Brian Feroldi (AbbVie): Biotech giant AbbVie hasn't gotten any love from the market recently. These ... | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher an... | If Regeneron Pharmaceuticals (NASDAQ: REGN) , Incyte Corporation (NASDAQ: INCY) , and AbbVie Inc. (NYSE: ABBV) aren't on your list of stocks to consider buying this month, you might want to add them. These three Motley Fool contributors think new approvals could help drive Regeneron Pharmaceuticals and Incyte higher an... |
25,318 | 2018-10-05 00:00:00 UTC | Roche's Hemlibra Receives FDA Approval for Label Expansion | ABBV | https://www.nasdaq.com/articles/roches-hemlibra-receives-fda-approval-for-label-expansion-2018-10-05 | null | null | RocheRHHBY announced that the FDA has approved a label expansion of its hemophilia drug, Hemlibra.
The drug is now approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, aged new born and older, with haemophilia A without factor VIII inhibitors.
The drug was app... | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free... | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free... | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free... | Apart from Hemlibra, Roche's hematology portfolio includes approved drugs like MabThera/Rituxan, Gazyva, Tecentriq, and Venclexta, in collaboration with AbbVie ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free... |
25,319 | 2018-10-03 00:00:00 UTC | Merck & Other Pharma Players Await FDA Decisions in October | ABBV | https://www.nasdaq.com/articles/merck-other-pharma-players-await-fda-decisions-october-2018-10-03 | null | null | In the United States, there has been a huge increase in FDA approvals for cancer and rare- to-treat diseases' drugs, thanks to efficient and effective regulatory processes. The FDA has already approved 41 novel drugs till September. Last year, the FDA had given nod to 34 new drugs till September and approved 46 drugs i... | Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysi... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysi... | Landmark decisions this year so far include J&J's JNJ Erleada (apalutamide) for pre-metastatic prostate cancer; Vertex Pharmaceuticals' cystic fibrosis (CF) medicine Symdeko; Amgen AMGN /Novartis NVS , Eli Lilly LLY and Teva Pharma's TEVA calcitonin gene-related peptide (CGRP) migraine treatments, Aimovig, Emgality and... |
25,320 | 2018-10-03 00:00:00 UTC | Here's Why J&J (JNJ) is a Good Bet in a Troubled Market | ABBV | https://www.nasdaq.com/articles/heres-why-jj-jnj-is-a-good-bet-in-a-troubled-market-2018-10-03 | null | null | In a bull market, it is easy to pick stocks and stay invested as shares of the majority of the listed companies move up on strong macroeconomic factors as well as positive sentiments. However, stock picking gets difficult in a bear market. A wrong choice can severely impact investors' portfolio as had been the case at ... | J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. J&J is also developing its and AbbVie's ABBV... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. J&J is also developing its and AbbVie's ABBV... | J&J is also developing its and AbbVie's ABBV Imbruvica in combination with Roche's RHHBY Rituxan to treat a rare form of Non-Hodgkin's lymphoma. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis ... |
25,321 | 2018-10-03 00:00:00 UTC | Noteworthy Wednesday Option Activity: FIT, ROST, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity-fit-rost-abbv-2018-10-03 | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Fitbit Inc (Symbol: FIT), where a total of 23,959 contracts have traded so far, representing approximately 2.4 million underlying shares. That amounts to about 45.2% of FIT's average daily trading volume over th... | Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading so far today, representing approximately 739,100 underlying shares of ABBV. Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And A... | Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.... | Below is a chart showing ROST's trailing twelve month trading history, with the $100 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 23,027 contracts thus far today. That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.... | That number of contracts represents approximately 2.3 million underlying shares, working out to a sizeable 44.3% of ABBV's average daily trading volume over the past month, of 5.2 million shares. Particularly high volume was seen for the $100 strike call option expiring November 16, 2018 , with 7,391 contracts trading ... |
25,322 | 2018-10-03 00:00:00 UTC | Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-is-poised-to-beat-earnings-estimates-again-2018-10-03 | null | null | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). This company, which is in the Zacks Large Cap Pharmaceuticals industry, shows potential for another earnings beat.
This d... | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98... | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98... | For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98 per share, representing a surprise of 1.01%. If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarter... | If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider AbbVie (ABBV). For the last reported quarter, AbbVie came out with earnings of $2 per share versus the Zacks Consensus Estimate of $1.98... |
25,323 | 2018-10-03 00:00:00 UTC | Gilead, HiFiBiO Collaborate to Develop T-Cell Receptors | ABBV | https://www.nasdaq.com/articles/gilead-hifibio-collaborate-to-develop-t-cell-receptors-2018-10-03 | null | null | Gilead Sciences, Inc . GILD announced that it entered into a collaboration agreement with HiFiBiO Therapeutics.
Both companies have entered into a research collaboration and license agreement to develop technology, supporting the discovery of neoantigen-reactive T-cell receptors (TCRs) for the potential treatment of va... | Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead S... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Given the persistent dec... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Given the persistent dec... | Given the persistent decline in HCV sales due to competitive pressure from companies like AbbVie, Inc. ABBV , the company is looking to HIV and newer avenues to boost its top line. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead S... |
25,324 | 2018-10-02 00:00:00 UTC | Here's Why Antares Pharma Jumped Higher Today | ABBV | https://www.nasdaq.com/articles/heres-why-antares-pharma-jumped-higher-today-2018-10-02 | null | null | What happened
Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for its testosterone treatment Xyosted.
The approval comes about a year after Antares disclosed that the FDA wasn't going to approve Xyosted on the first ... | The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. What happened Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for i... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. | The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Unlike Abbvie's gel, Xyosted is injected once a week. What happened Shares of Antares Pharma (NASDAQ: ATRS) were up 16.7% at 12:12 p.m. EDT on Tuesday after the company gained Food and Drug Administration (FDA) approval for i... | Unlike Abbvie's gel, Xyosted is injected once a week. The biggest seller, AbbVie 's (NYSE: ABBV) AndroGel, recorded sales of $577 million last year. Now what Antares is working on getting a sales force in place and plans to launch Xyosted before the end of this year. |
25,325 | 2018-10-02 00:00:00 UTC | The Zacks Analyst Blog Highlights: ExxonMobil, Disney, AbbVie, Bristol-Myers and United Continental | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-exxonmobil-disney-abbvie-bristol-myers-and-united | null | null | For Immediate Release
Chicago, IL - October 2, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS ... | Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for ExxonMobil, Disney & AbbVie The Zacks Research Daily presents the best research output of our analyst team. Toda... | Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. Click to get this free report United Continental Holdings, Inc. (UAL):... | Here are highlights from Monday's Analyst Blog: Top Analyst Reports for ExxonMobil, Disney & AbbVie The Zacks Research Daily presents the best research output of our analyst team. Click to get this free report United Continental Holdings, Inc. (UAL): Free Stock Analysis Report The Walt Disney Company (DIS): Free Stock ... | Today's Research Daily features new research reports on 12 major stocks, including ExxonMobil, Disney and AbbVie. Stocks recently featured in the blog include ExxonMobil XOM , Disney DIS , AbbVie ABBV , Bristol-Myers BMY and United Continental UAL . Here are highlights from Monday's Analyst Blog: Top Analyst Reports fo... |
25,326 | 2018-10-01 00:00:00 UTC | Health Care Sector Update for 10/01/2018: TLRY,MNTA,TARO,ABBV,REGN,MYL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-10012018-tlrymntataroabbvregnmyl-2018-10-01 | null | null | Top Health Care Stocks
JNJ Unch
PFE Unch
ABT Unch
MRK +0.42%
AMGN Unch
Health care stocks still were little changed ahead of Monday's opening bell.
Among health care stocks likely to move on news:
(+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trading after the cannabis grower said it received a license to... | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Among health care stocks likely to move on news: (+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trad... | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Top Health Care Stocks JNJ Unch PFE Unch ABT Unch Under the Health Canada sales license, High Park will be able t... | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. Among health care stocks likely to move on news: (+) Tilray ( TLRY ) jumped almost 9% in Monday's pre-market trad... | Moving forward, Momenta will work to advance M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's ( REGN ) Eylea drug treatment for eye disorders. AMGN Unch Health care stocks still were little changed ahead of Monday's opening bell. Among health care stocks l... |
25,327 | 2018-10-01 00:00:00 UTC | Health Care Sector Update for 10/01/2018: SYK,TLRY,TARO,MNTA,ABBV,REGN,MYL | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-10012018-syktlrytaromntaabbvregnmyl-2018-10-01 | null | null | Top Health Care Stocks
JNJ +1.03%
PFE +0.37%
ABT +0.85%
MRK +0.70%
AMGN -0.14%
Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a more than 0.4% gain for the NYSE Health Care Index in late trade. Shares of health care companies in the S&P 500 also were up over... | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. In other sector news: (+) Tilray ( TLRY ) jumped over 20% during Monday trading after the cannabis grower said Hea... | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a mor... | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a mor... | Moving forward, Momenta will continue work on M923, a biosimilar to AbbVie's ( ABBV ) Humira arthritis treatment, as well as M710, a biosimilar to Regeneron's (REGN) Eylea drug treatment for eye disorders. Health care stocks resisted some of the steeper declines for most industry sectors this afternoon, including a mor... |
25,328 | 2018-09-30 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Eli Lilly and Company | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-eli-lilly-and-company-2018-09-30 | null | null | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. Lilly's shares have surged around 26% in 2018 but that doesn't make it the better stock to buy right now.
To figure out which of these pharmaceutical stocks has the best... | This summer, AbbVie launched Orilissa, the first new treatment for endometriosis pain women have seen in over a decade, and it's expected to generate more than $1 billion annually within a few short years. This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) sto... | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low price of just 12.0 times e... | This has been a great year for Eli Lilly and Company 's (NYSE: LLY) shareholders, but AbbVie Inc. (NYSE: ABBV) stock has actually lost ground in 2018. At recent prices, Lilly shares offer a 2.1% dividend yield that's above the market average but far less than AbbVie stock offers. Right now, Lilly shares are priced for ... | Running the numbers Over the past three years, AbbVie's raised its dividend payout 88% higher, and investors can probably look forward to more big bumps in the years ahead. Right now, Lilly shares are priced for growth at 19.8 times this year's earnings expectations, while AbbVie shares can be picked up at the low pric... |
25,329 | 2018-09-28 00:00:00 UTC | Healthcare: 2 Hot Biotech Stocks on Our Radar | ABBV | https://www.nasdaq.com/articles/healthcare-2-hot-biotech-stocks-our-radar-2018-09-28 | null | null | There are lots of exciting biotech stocks that investors can consider owning in their growth portfolios. But according to Motley Fool Industry Focus: Healthcare analyst Shannon Jones and Fool contributor Todd Campbell, Neurocrine Biosciences (NASDAQ: NBIX) and Regenxbio (NASDAQ: RGNX) are two stocks that ought to be to... | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. | Then, they also had the backing and credibility of a well-funded partner, which was AbbVie (NYSE: ABBV) at the time, too. Also in late July 2018, in partnership with AbbVie, there is now a drug on the market called Orilissa. AbbVie right now has exclusive worldwide commercialization rights. |
25,330 | 2018-09-28 00:00:00 UTC | Pharma Stock Roundup: PFE, LLY Get Approval for New Drugs, Novartis to Cut Jobs | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-pfe-lly-get-approval-for-new-drugs-novartis-to-cut-jobs-2018-09-28 | null | null | It was a busy week for the big drugmakers. The FDA granted approval to Lilly's LLY calcitonin gene-related peptide ("CGRP") antibody, Emgality (galcanezumab) for migraine and Pfizer's PFE Vizimpro (dacomitinib) for an advanced lung cancer indication. Novartis NVS announced plans to cut more than 2000 jobs in Switzerlan... | The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Click to get this free report Novartis A... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report ... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report ... | The CHMP also gave a nod to AbbVie's ABBV application looking for approval of its leukemia drug Venclexta in combination with Roche's Rituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia ("CLL") who have received at least one prior therapy. Click to get this free report Novartis A... |
25,331 | 2018-09-28 00:00:00 UTC | AbbVie (ABBV) Stock Moves 0.47%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.47%3A-what-you-should-know-2018-09-28 | null | null | In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. The stock outpaced the S&P 500's daily of 0%. Meanwhile, the Dow gained 0.07%, and the Nasdaq, a tech-heavy index, added 0.06%.
Coming into today, shares of the drugmaker had lost 2.74% in the past month. In that... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47%... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.86 per share and revenue of $32.89 billion. In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report... | ABBV is currently a Zacks Rank #3 (Hold). In the latest trading session, AbbVie (ABBV) closed at $94.60, marking a +0.47% move from the previous day. Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. |
25,332 | 2018-09-27 00:00:00 UTC | Peek Under The Hood: EQWL Has 10% Upside | ABBV | https://www.nasdaq.com/articles/peek-under-hood-eqwl-has-10-upside-2018-09-27 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell Top 200 Equal ... | Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.00/share. Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justif... | Three of EQWL's underlying holdings with notable upside to their analyst target prices are AbbVie Inc (Symbol: ABBV), American International Group Inc (Symbol: AIG), and Booking Holdings Inc (Symbol: BKNG). Although ABBV has traded at a recent price of $94.18/share, the average analyst target is 15.74% higher at $109.0... | Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's un... | Below is a twelve month price history chart comparing the stock performance of ABBV, AIG, and BKNG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's un... |
25,333 | 2018-09-26 00:00:00 UTC | Gilead Is Undercutting Its Own Drugs: Here's Why | ABBV | https://www.nasdaq.com/articles/gilead-undercutting-its-own-drugs-heres-why-2018-09-26 | null | null | The U.S. drug pricing system is a mess. It's an absolute disaster. Just about every entity involved, from drug companies to consumers to insurers to the government, agrees that offering discounts off the list price is a convoluted way to sell a life-saving product.
The government has plans to try and fix it , but now G... | If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get steeper discounts than if there's only one superior medication to treat a disease. A few years ago, in protest to the lack of negotiation,... | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get st... | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get st... | And the lower actual cost to government plans could result in Gilead's drugs becoming the preferred drug over AbbVie's competing drugs. If pharmacy benefit managers (PBMs) can pit companies against one another, as they have with Gilead and rival AbbVie (NYSE: ABBV) , which sells Mavyret and Viekira Pak, they can get st... |
25,334 | 2018-09-25 00:00:00 UTC | Gilead (GILD) to Launch Generics for Leading HCV Treatments | ABBV | https://www.nasdaq.com/articles/gilead-gild-to-launch-generics-for-leading-hcv-treatments-2018-09-25 | null | null | Gilead Sciences, Inc . GILD announced that it plans to launch authorized generic versions of its leading hepatitis C virus (HCV) treatments - Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg).
The generic versions will be launched through a newly created subsidiary, Asegua Ther... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report G... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report G... |
25,335 | 2018-09-24 00:00:00 UTC | AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU | ABBV | https://www.nasdaq.com/articles/abbvie-roches-leukemia-drugs-combo-gets-chmp-backing-in-eu-2018-09-24 | null | null | AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. The label expansion application sought EU approval for the combination use of its cancer drug Venclexta and... | The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions. AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, In... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, In... | AbbVie, Inc.ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for label expansion of its leukemia drug, Venclexta. Venclexta is jointly marketed by AbbVie and Roche's Pharma arm, Genentech in the United States and by AbbVi... |
25,336 | 2018-09-24 00:00:00 UTC | SPYG, BA, ABBV, ADBE: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spyg-ba-abbv-adbe-etf-inflow-alert-2018-09-24 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $57.3 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 95,550... | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price ... | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year price ... | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of SPYG, in trading today Boeing Co. (Symbol: BA) is off about 0.7%, AbbVie Inc (Symbol: ABBV) is up about 0.9%, and Adobe Systems Inc (Symbol: ADBE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... |
25,337 | 2018-09-21 00:00:00 UTC | How Do Drugs Compete Against Each Other? | ABBV | https://www.nasdaq.com/articles/how-do-drugs-compete-against-each-other-2018-09-21 | null | null | It's easy to pick a winner when a medication is the only treatment for its indication. But when there's more than one drug on the market, how can investors tell which one will ultimately win more patient share?
In this prerecorded episode of Industry Focus: Healthcare , host Kristine Harjes and Motley Fool contributor ... | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson... | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson... | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson... | With real-world examples from companies like Merck (NYSE: MRK) , AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and so many more, the hosts explain what investors need to watch to compare similar drugs. That won approval in 2004, around the same time as another competing drug in the same indication from Johnson... |
25,338 | 2018-09-21 00:00:00 UTC | CRON Stock Is a Long-term Play With Near-Term Challenges | ABBV | https://www.nasdaq.com/articles/cron-stock-long-term-play-near-term-challenges-2018-09-21 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Currently, legal marijuana is one of the most exciting investment sectors. It also appears a resilient sector as well. After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ: CRON ) put up a remarkable performance, up 19% in just... | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . After demonstrating evidence of being technically overbought, Cronos Group (NASDAQ: CRON ) put up a remarkable performance, up 19% in just two days of trading. Canadian cannabis firm Tilray (NASDAQ: TLRY ), which recently... | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Currently, legal marijuana is one of the most exciting investment sectors. Canadian cannabis firm Tilray (NASDAQ: TLRY ), which recently received federal regu... | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . CRON Stock Is Risky in the Short Term, But a Winner in the Long Term The recent jump in Cronos stock represents the complicated nature of this investment. The Bottom Line for CRON Stock I'll reiterate my opinion regarding... | For example, famed drug-maker AbbVie (NYSE: ABBV ) has a cannabis-related therapy called Marinol . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Currently, legal marijuana is one of the most exciting investment sectors. CRON Stock Is Risky in the Short Term, But a Winner in the Long Term The recent jum... |
25,339 | 2018-09-21 00:00:00 UTC | Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status | ABBV | https://www.nasdaq.com/articles/pfizers-pneumococcal-vaccine-gets-breakthrough-therapy-status-2018-09-21 | null | null | Pfizer, Inc.PFE announced that it has received Breakthrough Therapy designation for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, from the FDA. The candidate is being developed as a preventive treatment for invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in ad... | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Fr... | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Fr... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilars in late-stage studies include Roche's RH... | Biosimilars in late-stage studies include Roche's RHHBY blockbuster oncology drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Fr... |
25,340 | 2018-09-20 00:00:00 UTC | Company News For Sep 20, 2018 | ABBV | https://www.nasdaq.com/articles/company-news-for-sep-20-2018-2018-09-20 | null | null | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials
Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its... | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its... | Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Copart, Inc. (CPRT): Free Stock Analysis Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. Tilray Inc.'s TLRY shares jumped 38.1% after the U.S.... | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its... | Tilray Inc.'s TLRY shares jumped 38.1% after the U.S. Drug Enforcement Administration gave approval to the company to import a marijuana product from Canada for clinical trials Shares of Facebook Inc. FB climbed 1.7% following news that the company has stepped up efforts to eliminate the spread of misinformation on its... |
25,341 | 2018-09-19 00:00:00 UTC | Validea Joel Greenblatt Strategy Daily Upgrade Report - 9/19/2018 | ABBV | https://www.nasdaq.com/articles/validea-joel-greenblatt-strategy-daily-upgrade-report-9192018-2018-09-19 | null | null | The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt . This value model looks for companies with high return on capital and earnings yields.
AUTOZONE, INC. ( AZO ) is a large-cap growth stock in the Auto & Truck Parts industry. The rating acco... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Inves... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimuma... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The rating according to our strategy based on Joel Greenblatt changed... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's Earnings Yield Inves... |
25,342 | 2018-09-19 00:00:00 UTC | AbbVie Faces California Insurance Department Suit for Humira | ABBV | https://www.nasdaq.com/articles/abbvie-faces-california-insurance-department-suit-for-humira-2018-09-19 | null | null | Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions.
California State Insu... | The lawsuit accused AbbVie of giving illegal kickbacks to doctors to prescribe its top-selling drug Humira, a treatment for rheumatoid arthritis and other inflammatory conditions. Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insurance department. AbbVie provides many ... | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Allergan plc (AGN): Free ... | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Amgen, Mylan and Samsung Bioepis/Biogen's Humira biosimilars are expected to be launched in the United... | AbbVie provides many support services to patients after they are prescribed Humira including sending nurses - called Ambassadors by the company - to their homes to assist them with Humira therapy on behalf of doctors. Shares of AbbVie, Inc.ABBV fell almost 3% on Tuesday following a lawsuit filed by the California insur... |
25,343 | 2018-09-19 00:00:00 UTC | Bristol-Myers' MM Drug Empliciti Application Validated by EMA | ABBV | https://www.nasdaq.com/articles/bristol-myers-mm-drug-empliciti-application-validated-by-ema-2018-09-19 | null | null | Bristol-Myers Squibb CompanyBMY announced that the European Medicines Agency (EMA) has validated its type II variation application, seeking approval for Empliciti in combination with Celgene Corporation's CELG Pomalyst and low-dose dexamethasone (EPd), for the treatment of adult patients with multiple myeloma who have ... | We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Bristol-Myers ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Bristol-Myers ... | We note that Bristol-Myers is co-developing Empliciti, with AbbVie, Inc. ABBV . Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis ... |
25,344 | 2018-09-18 00:00:00 UTC | 15 Best S&P 500 Stocks to Buy as the Markets Heat Up | ABBV | https://www.nasdaq.com/articles/15-best-sp-500-stocks-buy-markets-heat-2018-09-18 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
One of the more popular strategies among investors today is to seek out "home runs." These are lesser-known companies that have tremendous upside potential, but carry the risk of collapsing should business prospects go awry. While a balanced portfolio allow... | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slight... | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slight... | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slight... | 10 Best High-Growth Stocks for Young Investors With that said, let's dive into the best S&P 500 stocks to buy: S&P 500 Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Biopharmaceutical firm AbbVie (NYSE: ABBV ) has been a fixture of the S&P 500 index for almost six years. Since the January opener, ABBV is only slight... |
25,345 | 2018-09-18 00:00:00 UTC | Commit To Purchase AbbVie At $47.50, Earn 2.7% Using Options | ABBV | https://www.nasdaq.com/articles/commit-purchase-abbvie-4750-earn-27-using-options-2018-09-18 | null | null | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June 2020 put at the $47.50 strike, which h... | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlig... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the J... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $47.50 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the J... | Investors eyeing a purchase of AbbVie Inc (Symbol: ABBV) stock, but cautious about paying the going market price of $95.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ABBV's upside potential the way owning share... |
25,346 | 2018-09-18 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-09-18 | null | null | Healthcare stocks are handily outpacing the S&P 500 index so far in 2018. With the aging demographics in the U.S. and other major countries serving as a significant tailwind, it's possible that healthcare will remain a hot area for investors for decades to come.
We asked three Motley Fool contributors which healthcare ... | Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky stock. More important, AbbVie claims several approved products that are already growing by leaps and bounds. | Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky... | The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky... | The stock is trading at less than 11 times expected earnings, making AbbVie one of the best healthcare picks around, in my view. Their top picks were AbbVie (NYSE: ABBV) , Mednax (NYSE: MD) , and Xencor (NASDAQ: XNCR) . Not as risky as it might seem Keith Speights (AbbVie): I get why AbbVie might seem like a very risky... |
25,347 | 2018-09-17 00:00:00 UTC | The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-jpmorgan-mastercard-abbvie-cvs-health-and-estee-lauder | null | null | For Immediate Release
Chicago, IL - September 17, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include JPMorgan JPM , Mastercard... | Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMorgan, Mastercard and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Today's R... | Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis... | Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMorgan, Mastercard and AbbVie The Zacks Research Daily presents the best research output of our analyst team. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report The ... | Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Mastercard and AbbVie. Stocks recently featured in the blog include JPMorgan JPM , Mastercard MA , AbbVie ABBV , CVS Health CVS and Estee Lauder EL . Here are highlights from Thursday's Analyst Blog: Top Stock Reports for JPMor... |
25,348 | 2018-09-17 00:00:00 UTC | Pfizer's Skin Disease Candidates Positive in Mid-Stage Study | ABBV | https://www.nasdaq.com/articles/pfizers-skin-disease-candidates-positive-in-mid-stage-study-2018-09-17 | null | null | Pfizer Inc.PFE announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata ("AA").
Both the candidates met the primary endpoint of improving hair regrowth on the sca... | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Repo... | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Repo... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Biosimilars in late-stage development include ... | Biosimilars in late-stage development include biosimilar versions of Roche's RHHBY blockbuster cancer drugs Rituxan and Avastin, and AbbVie's ABBV blockbuster rheumatoid arthritis drug, Humira. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Repo... |
25,349 | 2018-09-17 00:00:00 UTC | Why Gilead Stock Is a Sleepy Giant Waiting to Break Out | ABBV | https://www.nasdaq.com/articles/why-gilead-stock-sleepy-giant-waiting-break-out-2018-09-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Gilead Sciences (NASDAQ: GILD ) stock is stuck in a range and for good reason. The markets cannot decide if its quarterly revenue declines are permanent or if the company's growth is reaccelerating again. Yet if investors hold Gilead stock and collect its 3... | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. Yet if investors hold Gilead stock and collect its 3%... | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. 6 Monthly Dividend Stocks to Buy Minimal Impact on Gi... | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. 6 Monthly Dividend Stocks to Buy Minimal Impact on Gi... | More importantly, compared to the RA drug made by AbbVie Inc. (NYSE: ABBV ), Gilead's treatment has a better safety profile and is more effective. Further, the relatively clean safety numbers of Gilead's drug should help it compete effectively with AbbVie's product. Even though HIV patients have many treatment options,... |
25,350 | 2018-09-16 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 9/16/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-9162018-2018-09-16 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap gr... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, I... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock i... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's Care Coordination services include coordinated delivery of pharmacy services, vascular, cardiovascular and endovascular specialty ... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Company Description: Acadia Healthcare Company, Inc. is a provider of behavioral healthcare services, with operations in the United States and t... |
25,351 | 2018-09-14 00:00:00 UTC | Pharma/Biotech Stocks to Watch This Prostate Cancer Month | ABBV | https://www.nasdaq.com/articles/pharma-biotech-stocks-to-watch-this-prostate-cancer-month-2018-09-14 | null | null | September is observed as National Prostate Cancer Month to raise awareness about the disease, which is the leading cause of death in men, second only to skin cancer in the United States. A light blue ribbon is used as a symbol to raise awareness about prostate cancer.
About the Disease
Prostate cancer is a very complex... | AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE):... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESA... | Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report TESA... | AbbVie ABBV provides a palliative treatment for advanced prostate cancer, Lupron. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE):... |
25,352 | 2018-09-14 00:00:00 UTC | Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-mtum-abbv-isrg-spgi-2018-09-14 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $130.0 million dollar outflow -- that's a 1.3% decrease week over week (from 87,950,000 to 86,... | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one ye... | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one ye... | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at... | Among the largest underlying components of MTUM, in trading today AbbVie Inc (Symbol: ABBV) is off about 0.9%, Intuitive Surgical Inc (Symbol: ISRG) is up about 2%, and S&P Global Inc (Symbol: SPGI) is higher by about 0.6%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one ye... |
25,353 | 2018-09-14 00:00:00 UTC | A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis | ABBV | https://www.nasdaq.com/articles/brawl-brewing-between-abbvie-and-gilead-sciences-arthritis-2018-09-14 | null | null | There are more than 23 million people worldwide with rheumatoid arthritis, and despite current treatments, many patients fail to achieve disease remission or significant reductions in disease activity. The size of the addressable market and need for new drugs have made this indication a focus of drug development and ne... | Results from upadacitinib's phase 3 rheumatoid arthritis trials have already been reported, and AbbVie anticipates filing for an FDA OK before the end of 2018. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and G... | Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYS... | The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line. AbbVie's $18 billion-per-year Humira is o... | Since targeting JAK is effective, but there's still room for improvement in safety, AbbVie and Gilead Sciences are each advancing new drugs that target JAK more selectively. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYS... |
25,354 | 2018-09-14 00:00:00 UTC | Roche's Child Arthritis Drug's New Formulation Gets FDA Nod | ABBV | https://www.nasdaq.com/articles/roches-child-arthritis-drugs-new-formulation-gets-fda-nod-2018-09-14 | null | null | Roche Holding AG'sRHHBY subsidiary, Genentech announced that the FDA has approved a label expansion for its arthritis drug, Actemra. The FDA approved a subcutaneous (SC) formulation - a prefilled syringe that can be injected at home -of Actemra for the treatment of active systemic juvenile idiopathic arthritis (SJIA) i... | Other drugs marketed for this indication are Abbvie Inc.'s ABBV Humira and Bristol-Myers Squibb Company's BMY Orencia. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers S... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report To read this article on Zacks.com click here. Other drugs marketed for ... |
25,355 | 2018-09-13 00:00:00 UTC | Should Value Investors Consider AbbVie (ABBV) Stock Now? | ABBV | https://www.nasdaq.com/articles/should-value-investors-consider-abbvie-abbv-stock-now-2018-09-13 | null | null | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking ... | Broad Value Outlook In aggregate, AbbVie currently has a Zacks Value Style Score of B, putting it into the top 40% of all stocks we cover from this look. In particular, it is worth noting that the company has a Growth grade of B and a Momentum score of D. This gives ABBV a Zacks VGM score-or its overarching fundamental... | If we focus on the long-term PE trend, AbbVie's current PE level puts it below its midpoint over the past five years. You can see the consensus estimate trend and recent price action for the stock in the chart below: AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Even though AbbVie ... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. Y... | Let's put AbbVie Inc.ABBV stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. O... |
25,356 | 2018-09-12 00:00:00 UTC | AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia | ABBV | https://www.nasdaq.com/articles/abbvie-gets-fda-nod-for-venclexta-label-expansion-in-leukemia-2018-09-12 | null | null | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study.
In case of MRD-negativity, chronic lymphocytic leukemia ("CLL") cells fall below the ratio of 1:10000 l... | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. Also, in July, AbbVie filed a regulatory application in the United States for Venclexta in acute myeloi... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Repor... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Repor... | AbbVie, Inc.ABBV announced that the FDA has approved the label expansion of its cancer drug Venclexta and Roche's RHHBY Rituxan to include minimal residual disease ("MRD")-negativity data from phase III MURANO study. AbbVie's shares have lost 3.7% this year so far against the industry 's gain of 4.7%. Also, in July, Ab... |
25,357 | 2018-09-12 00:00:00 UTC | 5 Growth Stocks to Buy for Reliable Income in Retirement | ABBV | https://www.nasdaq.com/articles/5-growth-stocks-buy-reliable-income-retirement-2018-09-12 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Once investors retire, the priority usually turns to income. Here, they want their assets to generate as much cash as they can with as little risk. In today's lending environment, CDs and bonds will probably not produce enough money. They could turn to dist... | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large ... | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large ... | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large ... | 7 Dividend Stocks to Buy Amid This Tough Market Environment No matter the choice, if one desires to use growth stocks in retirement, these five equities could hold an investor in good stead: Growth Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 4.1% Health issues often compel retirees to spend large ... |
25,358 | 2018-09-07 00:00:00 UTC | Vertex Completes Enrollment in Triple Combination Studies | ABBV | https://www.nasdaq.com/articles/vertex-completes-enrollment-in-triple-combination-studies-2018-09-07 | null | null | Vertex Pharmaceuticals IncorporatedVRTX announced the completion of enrollment in two phase III studies evaluating its next-generation corrector, VX-659, in combination with tezacaftor and Kalydeco (ivacaftor) for treating cystic fibrosis ("CF"). While one study is evaluating the triple combination regimen in patients ... | We remind investors that Galapagos NV GLPG and its partner AbbVie ABBV announced disappointing data from the phase II study of their CF candidate, GLPG2737, in June. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapa... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We re... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. We re... |
25,359 | 2018-09-07 00:00:00 UTC | Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC | ABBV | https://www.nasdaq.com/articles/daily-dividend-report-amt-rcl-abbv-amat-nue-krc-2018-09-07 | null | null | American Tower Corporation ( AMT ) declared its quarterly cash distribution of $0.79 per share on shares of the Company's common stock. The distribution is payable on October 17, 2018 to such stockholders of record at the close of business on September 28, 2018.
Royal Caribbean Cruises ( RCL ) declared a quarterly divi... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly d... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly d... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Royal Caribbean Cruises ( RCL ) declared a quarterly d... | AbbVie ( ABBV ) declared a quarterly cash dividend of $0.96 per share. VIDEO: Daily Dividend Report: AMT, RCL, ABBV, AMAT, NUE, KRC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. American Tower Corporation ( AMT ) declared its quarte... |
25,360 | 2018-09-06 00:00:00 UTC | Notable ETF Inflow Detected - MTUM, BA, JPM, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-mtum-ba-jpm-abbv-2018-09-06 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $139.9 million dollar inflow -- that's a 1.4% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 1.3%, JPMorgan Chase & Co (Symbol: JPM) is trading flat, and AbbVie Inc (Symbol: ABBV) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... |
25,361 | 2018-09-06 00:00:00 UTC | 3 Top Big Pharma Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/3-top-big-pharma-stocks-buy-now-2018-09-06 | null | null | Some people stick the word "big" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term "big pharma," though, I'm not intending to be derogatory. My use of the label is to simply refer to the biggest drugmakers on the market.
I think there are three big... | In addition to its strong current lineup, AbbVie's pipeline looks very promising, with immunology drugs risankizumab and upadacitinib especially standing out. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GIL... | AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. AbbVie delivers on both very well. | AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie, Gilead Sciences, and Pfizer. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like real... | AbbVie There are two things that investors especially want when they buy a big pharma stock -- growth and dividends. AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) look like really good picks for the long run. AbbVie delivers on both very well. |
25,362 | 2018-09-05 00:00:00 UTC | Forget CRISPR Therapeutics: Vertex Pharmaceuticals Incorporated Is a Better Biotech Stock | ABBV | https://www.nasdaq.com/articles/forget-crispr-therapeutics-vertex-pharmaceuticals-incorporated-better-biotech-stock-2018 | null | null | Gene-editing pioneer CRISPR Therapeutics AG (NASDAQ: CRSP) has sparked imaginations and puffed up portfolios. Before you dive in, though, you might want to take a look at its much larger partner, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) .
CRISPR Therapeutics recently became the first among its U.S.-traded pee... | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Adding it to Symdeko led to an 11% lu... | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Before you dive in, though, you might... | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. Vertex shareholders might feel a slig... | A partnership between Galapagos NV (NASDAQ: GLPG) and AbbVie Inc. (NYSE: ABBV) is arguably furthest ahead, but the smaller biotech also began reviewing the future of its collaboration after releasing less than thrilling mid-stage results for a partnered candidate earlier this year. If CTX001 flops, as most experimental... |
25,363 | 2018-09-04 00:00:00 UTC | Is Now a Good Time to Buy Gilead Sciences? | ABBV | https://www.nasdaq.com/articles/now-good-time-buy-gilead-sciences-2018-09-04 | null | null | Fierce competition in the hepatitis C market has caused Gilead Sciences ' (NASDAQ: GILD) sales and share price to slide, but the dividend-paying company remains profitable and there are catalysts on the horizon that could reignite interest. Is now a good time to add this biotech behemoth to portfolios?
By the numbers
G... | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C marke... | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C marke... | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. Fierce competition in the hepatitis C marke... | It's likely going to be unable to maintain that $4 billion run rate in hepatitis C sales going forward because AbbVie 's (NYSE: ABBV) latest drug in the indication, Mavyret, continues gaining steam. In Q2, AbbVie's hepatitis C revenue grew more than 100% to nearly $1 billion. The company's hepatitis C drug sales fell 6... |
25,364 | 2018-09-04 00:00:00 UTC | Vertex Inks Reimbursement Agreement for Orkambi in Australia | ABBV | https://www.nasdaq.com/articles/vertex-inks-reimbursement-agreement-for-orkambi-in-australia-2018-09-04 | null | null | Vertex Pharmaceuticals Inc.VRTX announced that an agreement has been finalized with the Australian Government, which will allow reimbursement on cystic fibrosis ("CF") drug, Orkambi (lumacaftor + ivacaftor) in the country. This follows the positive recommendation from Pharmaceutical Benefits Advisory Committee ("PBAC")... | Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analys... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreo... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analysis Report Corbus Pharmaceuticals Holdings, Inc. (CRBP): Free Stock Analysis Report To read this article on Zacks.com click here. Moreo... | Moreover, Galapagos' collaboration partner, AbbVie ABBV opted out of the development of a triple combination regimen for CF patients. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Galapagos NV (GLPG): Free Stock Analys... |
25,365 | 2018-09-04 00:00:00 UTC | These Monthly Dividend Stocks Are Set to Surge (and pay up to 6.8%) | ABBV | https://www.nasdaq.com/articles/these-monthly-dividend-stocks-are-set-surge-and-pay-68-2018-09-04 | null | null | By Brett Owens
If youaEURtmre like most folks, youaEURtmre so used to collecting dividends quarterly that it may not have occurred to you that your portfolio can pay you every month.
But itaEURtms true, thanks to a small set of stocks that delivers cash payouts month in and month out like clockwork (IaEURtmll reveal 3 ... | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in J... | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in J... | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in J... | Check out this chart showing your income from a 5-stock portfolio with $100k invested in each of 5 Dividend Aristocrats boasting relatively high yields: AT&T ( T ), AbbVie ( ABBV ), ExxonMobil ( XOM ) , Cardinal Health ( CAH ) and Consolidated Edison ( ED ): A Lumpy Cash Stream Your cash flow ranges from just $926 in J... |
25,366 | 2018-08-31 00:00:00 UTC | Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-approval-of-nvs-abbv-cancer-drugs-mrks-hiv-drug-in-focus-2018-08-31 | null | null | This week was ruled by FDA and EU approvals for new cancer therapies as well as line extensions of cancer drugs. These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHH... | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's can... | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. (Read more: AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma ) J&J/Bayer's X... | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report N... | These included EU approvals for Novartis' NVS CAR-T Kymriah and Tafinlar plus Mekinist combination for a third indication and FDA approval for AbbVie ABBV /J&J's JNJ Imbruvica in combination with Roche's RHHBY Rituxan for a rare cancer. AbbVie's Imbruvica+Rituxan Combo Gets FDA Nod for Rare Cancer: AbbVie and J&J's can... |
25,367 | 2018-08-31 00:00:00 UTC | Do the Risks in Marijuana Stocks Outweigh the Rewards? | ABBV | https://www.nasdaq.com/articles/do-risks-marijuana-stocks-outweigh-rewards-2018-08-31 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Marijuana stocks are hot now, as is the social and political climate around them.
But true investors know that if you're going to be a successful investor you have to be able to spot objective opportunities and not be pulled by emotional or political feelin... | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. | For example, in the biotech space AbbVie (NASDAQ: ABBV ) is major player. ABBV also has other derivatives in its pipeline and will likely be a major player in this new sector. What's more, ABBV and SMG are solid stocks on their own merit and much safer than the newer cannabis stocks. |
25,368 | 2018-08-28 00:00:00 UTC | AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma | ABBV | https://www.nasdaq.com/articles/abbvies-imbruvica-combo-gets-fda-nod-for-rare-lymphoma-2018-08-28 | null | null | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of No... | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of No... | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of No... | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of No... | AbbVie, Inc.ABBV and partner J&J JNJ announced that the FDA has granted approval to a supplemental new drug application (sNDA) looking for label expansion of their cancer drug Imbruvica in combination use with Roche's RHHBY Rituxan (rituximab) for the treatment of Waldenström's macroglobulinemia (WM), a rare form of No... |
25,369 | 2018-08-28 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-2018-08-28 | null | null | In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. This move lagged the S&P 500's daily gain of 0.03%. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq added 0.15%.
Coming into today, shares of the drugmaker had gained 7.18% in the past month. In that... | In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.85 per share and revenue of $32.83 billion. Investors will be hoping for strength from ABBV as it approaches its next earnings release, wh... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings releas... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $7.85 per share and revenue of $32.83 billion. In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, wh... | ABBV currently has a Zacks Rank of #3 (Hold). In the latest trading session, AbbVie (ABBV) closed at $97.30, marking a -0.84% move from the previous day. Investors will be hoping for strength from ABBV as it approaches its next earnings release, which is expected to be October 26, 2018. |
25,370 | 2018-08-27 00:00:00 UTC | We Did The Math FTXH Can Go To $26 | ABBV | https://www.nasdaq.com/articles/we-did-math-ftxh-can-go-26-2018-08-27 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuti... | Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: ... | Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. Three of FTXH's underlying holdings with notable ... | Similarly, HRTX has 30.45% upside from the recent share price of $39.25 if the average analyst target price of $51.20/share is reached, and analysts on average are expecting ABBV to reach a target price of $109.07/share, which is 11.98% above the recent price of $97.40. Three of FTXH's underlying holdings with notable ... | Below is a twelve month price history chart comparing the stock performance of BPMC, HRTX, and ABBV: Combined, BPMC, HRTX, and ABBV represent 9.04% of the First Trust Nasdaq Pharmaceuticals ETF. Three of FTXH's underlying holdings with notable upside to their analyst target prices are Blueprint Medicines Corp (Symbol: ... |
25,371 | 2018-08-27 00:00:00 UTC | AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-up-3.7-since-last-earnings-report%3A-can-it-continue-2018-08-27 | null | null | It has been about a month since the last earnings report for AbbVie (ABBV). Shares have added about 3.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? Before we dive into how investors and analysts have re... | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the sec... | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the sec... | It has been about a month since the last earnings report for AbbVie (ABBV). Will the recent positive trend continue leading up to its next earnings release, or is AbbVie due for a pullback? AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the sec... | AbbVie Tops Q2 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the second quarter of 2018. Previously, AbbVie expected operating margin to be approximately 43.5% of sales. It has been about a month since the last earnings report for AbbVie (ABBV). |
25,372 | 2018-08-26 00:00:00 UTC | 3 Dividend Stocks to Buy on Sale | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-buy-sale-2018-08-26 | null | null | Buy high or buy low? Probably the best answer is to do both -- depending on the unit of measure.
Buying stocks with relatively high dividend yields can prove to be a really smart move over the long term. Over the last 10 years, nearly 30% of the total return generated by the S&P 500 index came from reinvesting dividend... | *Stock Advisor returns as of August 6, 2018 Keith Speights owns shares of AbbVie and has performed consulting services in the past for Abbott Labs. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | However, I think that AbbVie could generate the highest total returns for investors because of its growth prospects. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | But I think that buying stocks that also have high earnings growth prospects -- like AbbVie -- is even smarter. I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. | * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and AbbVie wasn't one of them! I'd put AbbVie (NYSE: ABBV) , AT&T (NYSE: T) , and Cummins (NYSE: CMI) at the top of the list. AbbVie AbbVie claims one of the best dividends in the healthcare sector. |
25,373 | 2018-08-25 00:00:00 UTC | 3 Top Value Stocks to Buy in August | ABBV | https://www.nasdaq.com/articles/3-top-value-stocks-buy-august-2018-08-25 | null | null | The idea of investing in "value" stocks is simple enough: to buy shares of a business that are trading for less than they're worth.
But if finding, buying, and holding the market's most attractive value stocks were easy, everyone would be doing it. So to help get you started, we asked three top Motley Fool contributors... | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A... | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A... | But whether we're talking about Facebook's massive pullback last month, industry pessimism driving Kroger to mouthwatering levels, or AbbVie's growth potential and high yield, we like their chances of doing just that. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A... | However, AbbVie makes a lot more money on the drug in the U.S., where Humira shouldn't encounter biosimilar competition until 2023. Read on to learn why they like Facebook (NASDAQ: FB) , Kroger (NYSE: KR) , and AbbVie (NYSE: ABBV) . A big pharma bargain Keith Speights (AbbVie): When around 60% of a company's total reve... |
25,374 | 2018-08-25 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Merck & Co., Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-merck-co-inc-2018-08-25 | null | null | The number of American adults over the age of 85 will more than double over the next 22 years and this group's more dependent on expensive medicines than ever. This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right directio... | Humira isn't the fastest-growing product in AbbVie's lineup, but it's expanding fast enough to make it the company's lead growth driver by a long shot. This long-running megatrend will probably drive overall demand for products from AbbVie Inc. (NYSE: ABBV) and Merk & Co., Inc. (NYSE: MRK) in the right direction for de... | Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? This long-running megatrend will probably drive overall demand for products from AbbVie I... | Merck and AbbVie offer dividends driven by sales of innovative new drugs and a chance to enjoy strong sales growth in the years to come, but which is poised to grow along with the population of older adults in the U.S. and abroad? If you've seen television commercials over the past several years, you probably realize t... | If you've seen television commercials over the past several years, you probably realize that Humira's an important drug, but did you know sales of the rheumatoid arthritis injection AbbVie launched 16 years ago will probably achieve $20 billion in sales this year? AbbVie's the better stock to buy right now, hands down.... |
25,375 | 2018-08-23 00:00:00 UTC | AbbVie Posts Positive Data on Elagolix for Uterine Fibroids | ABBV | https://www.nasdaq.com/articles/abbvie-posts-positive-data-on-elagolix-for-uterine-fibroids-2018-08-23 | null | null | AbbVie Inc . ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. Outcomes from the phase III ELARIS UF-EXTEND (M12-816) trial demonstrated that Elagolix (300 mg twice daily) in combinatio... | ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. AbbVie Inc . However, shares of AbbVie have lost 0.9% year to date versus the industry's increase of 5.4%. | ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uterine fibroids in women. AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #... | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Illumina, Inc. (ILMN): Free Stock Analysis Report G... | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote Zacks Ranks AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie Inc . ABBV and its partner Neurocrine Biosciences announced positive top-line data from phase III ELARIS UF-EXTEND extension study on Elagolix for the treatment of uter... |
25,376 | 2018-08-22 00:00:00 UTC | Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-08222018-argxphgsngx-2018-08-22 | null | null | Top Health Care Stocks
JNJ -0.45%
PFE +0.14%
ABT +1.43%
MRK -0.16%
AMGN +0.46%
Health care stocks were edging higher Wednesday afternoon, including a nearly 0.2% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were up almost 0.2% as a group while the Nasdaq... | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie sec... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech com... | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie sec... | Among health care stocks moving on news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to license the biotech company's ARGX-115 immuno-oncology antibody. The companies signed a licensing agreement for ARGX-115 about two years ago, with AbbVie sec... |
25,377 | 2018-08-22 00:00:00 UTC | 3 Undervalued Dividend Stocks to Buy | ABBV | https://www.nasdaq.com/articles/3-undervalued-dividend-stocks-to-buy-2018-08-22 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Finding undervalued stocks in today's market is a tricky business. If you're a value investor who is looking to beef up your retirement portfolio, it's essential to choose firms that have fallen out of favor with Mr. Market but look poised to make a comebac... | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is... | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is... | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. However, there are certainly deals to be had within the industry, and AbbVie (NYSE: ABBV ) is... | Dividend Stocks to Buy: AbbVie (ABBV) Source: Shutterstock Dividend Yield: 3.9% Big pharma has been a turbulent space over the past few years as concerns regarding drug pricing have weighed on investor sentiment in the sector. The Humira concerns are certainly something to keep in mind - the drug makes up more than hal... |
25,378 | 2018-08-22 00:00:00 UTC | Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-08222018-exaspfeargxphgsngx-2018-08-22 | null | null | Top Health Care Stocks
JNJ -0.55%
PFE -0.21%
ABT +1.47%
MRK -0.12%
AMGN +0.38%
Health care stocks were poised to finish with a a small gain on Wednesday, including a nearly 0.2% rise for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were up almost 0.2% as a group ... | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to licen... | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to licen... | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to licen... | The stock is receiving an added boost this afternoon when analysts at BTiG responded Wednesday by raising their price target for Exact Science shares by $20 to $90 apiece In other sector news: + argenx SE ( ARGX ) was nearly 5% higher during Wednesday trading after AbbVie ( ABBV ) exercised an exclusive option to licen... |
25,379 | 2018-08-21 00:00:00 UTC | Trade of the Day: AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/trade-of-the-day%3A-abbvie-abbv-2018-08-21 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today.
Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufac... | Wall Street is starting to pay attention to the stock again, and traders have pushed the ABBV up through down-trending resistance at ~$97 per share - completing an inverted "head-and-shoulders" bullish reversal pattern. InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this Ab... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufac... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Major drug-manufacturer ABBV is still trying to bounce back from the massive late-Marc... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips To receive further updates on this AbbVie (NYSE: ABBV ) trade as well as an alert when it's time to take profits, sign up for a risk-free trial of SlingShot Trader today. Today, we are opening a new bullish trade on AbbVie (NYSE: ABBV ) . Major drug-manufac... |
25,380 | 2018-08-20 00:00:00 UTC | 8 Undervalued Biotech Stocks to Watch | ABBV | https://www.nasdaq.com/articles/8-undervalued-biotech-stocks-to-watch-2018-08-20 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA: XBI ) is up double digits since January's opening session. That said, the market movement has been anything... | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing thr... | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing thr... | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing thr... | 10 Dividend Aristocrats You Never Have to Worry About So without further ado, here are eight undervalued biotech stocks to watch: Undervalued Biotech Stocks to Watch: AbbVie (ABBV) Source: Shutterstock If I could describe AbbVie (NYSE: ABBV ) in two words, I would use the terms revenue and earnings. In the trailing thr... |
25,381 | 2018-08-19 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 8/19/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-8192018-2018-08-19 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
EMERGENT BIOSOLUTIONS INC ( EBS ) is ... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company focuses on protecting and enhancing life by providing spe... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimuma... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company's principal business is owning and operating, through its... |
25,382 | 2018-08-14 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2018-08-14 | null | null | Perhaps no blending of words applies to the pharmaceutical industry better than "frenemies" -- the combination of "friends" and "enemies." The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) .
The two gi... | AbbVie's pipeline, which market research firm EvaluatePharma ranked as the second-best in the industry , is even more important to the company's growth. The word accurately describes the relationships of quite a few big pharma companies, including two of the biggest: AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ... | The case for Johnson & Johnson Does Johnson & Johnson beat AbbVie on growth prospects, valuation, and dividend yield? The stock trades at 15 times expected earnings, and J&J's dividend currently yields 2.74% -- solid, but not as good as AbbVie's yield. At least for the next few years, I think AbbVie stock will generate... | Tthe company has increased its dividend by 140% since 2013, making AbbVie's dividend one of the fastest-growing dividends on the market. The case for Johnson & Johnson Does Johnson & Johnson beat AbbVie on growth prospects, valuation, and dividend yield? The word accurately describes the relationships of quite a few bi... | But AbbVie's primary sources of growth from its current lineup of approved products will be cancer drugs Imbruvica and Venclexta, hepatitis C drug Mavyret, and endometriosis drug Orilissa. Tthe company has increased its dividend by 140% since 2013, making AbbVie's dividend one of the fastest-growing dividends on the ma... |
25,383 | 2018-08-13 00:00:00 UTC | Noteworthy ETF Inflows: MTUM, BA, JPM, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows-mtum-ba-jpm-abbv-2018-08-13 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $153.6 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (fr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year price pe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is up about 0.4%, JPMorgan Chase & Co (Symbol: JPM) is down about 0.1%, and AbbVie Inc (Symbol: ABBV) is up by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... |
25,384 | 2018-08-13 00:00:00 UTC | Why Enanta Stock Is Still a Strong Buy With Huge Upside | ABBV | https://www.nasdaq.com/articles/why-enanta-stock-still-strong-buy-huge-upside-2018-08-13 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Enanta Pharmaceuticals (NASDAQ: ENTA ) has been in the news recently. Unfortunately, it isn't for the reasons that I'm so bullish on ENTA stock.
Although Enanta stock is off almost 30% in the past month, it is still up 52% year-to-date and up nearly 130% fo... | Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market share in this lucrative sector. For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells ... | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market... | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market... | For example, ENTA has two big drugs that it has co-developed with big pharma player AbbVie (NYSE: ABBV ). ABBV sells them as MAVYRET and VIEKIRA PAK. Why ENTA Stock Is Still Worth a Look The fear that's reflected in the selloff is that other PBMs may take the same path as ESRX and that will certainly hurt ABBV's market... |
25,385 | 2018-08-08 00:00:00 UTC | Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut | ABBV | https://www.nasdaq.com/articles/mylan-myl-q2-earnings-and-revenues-miss-guidance-cut-2018-08-08 | null | null | MylanMYL reported dismal results for second-quarter 2018 as earnings and sales both missed estimates. The company also lowered its guidance.
Adjusted earnings of $1.07 per share missed the Zacks Consensus Estimate of $1.23 and were down from $1.10 reported in the year-ago quarter.
Second-quarter revenues of $2.81 billi... | The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read ... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also issues a positive opinion on th... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP also issues a positive opinion on th... | The CHMP also issues a positive opinion on the biosimilar of AbbVie's ABBV Humira. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read ... |
25,386 | 2018-08-07 00:00:00 UTC | Get Paid While You Wait: 3 Top Dividend Stocks in Healthcare | ABBV | https://www.nasdaq.com/articles/get-paid-while-you-wait-3-top-dividend-stocks-healthcare-2018-08-07 | null | null | Don't underestimate the power of dividends -- especially when you reinvest those dividends over a long period of time. You might be surprised by how much reinvesting dividends can boost your total returns.
But what dividend stocks should you buy? I'd recommend turning your attention to the healthcare sector. It account... | AbbVie has a great dividend and tremendous growth prospects, and the stock looks really cheap, with shares trading at less than 11 times expected earnings. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. | Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. AbbVie should have plenty of financial flexibility to keep those dividend hikes coming in future years, too. | AbbVie has a great dividend and tremendous growth prospects, and the stock looks really cheap, with shares trading at less than 11 times expected earnings. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . AbbVie AbbVie's dividend currently yields a little over 4%. | AbbVie AbbVie's dividend currently yields a little over 4%. That's plenty of time for AbbVie's other drugs and pipeline candidates to ramp up sales. Three that I especially like are AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Welltower (NYSE: WELL) . |
25,387 | 2018-08-05 00:00:00 UTC | Better Buy: Pfizer Inc. vs. AbbVie Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-pfizer-inc-vs-abbvie-inc-2018-08-05 | null | null | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Despite a recent thumping, the stock has delivered a 236% total return to investors who have held on since its inception in 2013. Investors who bought the stock earlier this year, though, have a lot less to smile about.... | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue cli... | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue cli... | Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue climbing over the long haul. Over the past year, AbbVie and Pfizer have used 42% and 53% of free cash fl... | This year, AbbVie Inc. (NYSE: ABBV) showed us why it's important to stay invested for the long haul. Pfizer Inc. 's (NYSE: PFE) diverse line of newer drugs has kept things moving at a pace that pales in comparison with AbbVie's, but a recent earnings report has investors feeling confident the top line will continue cli... |
25,388 | 2018-08-03 00:00:00 UTC | Noteworthy ETF Outflows: MTUM, BA, ABBV, COST | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows-mtum-ba-abbv-cost-2018-08-03 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Momentum Factor ETF (Symbol: MTUM) where we have detected an approximate $169.5 million dollar outflow -- that's a 1.8% decrease week over week (from 83,600,000 to 82,... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year pr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year pr... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of MTUM, in trading today Boeing Co. (Symbol: BA) is off about 0.4%, AbbVie Inc (Symbol: ABBV) is up about 0.7%, and Costco Wholesale Corp (Symbol: COST) is higher by about 0.3%. For a complete list of holdings, visit the MTUM Holdings page » The chart below shows the one year pr... |
25,389 | 2018-07-31 00:00:00 UTC | 5 Top Stock Trades for Wednesday — Is Procter Finally a Buy? | ABBV | https://www.nasdaq.com/articles/5-top-stock-trades-for-wednesday-is-procter-finally-a-buy-2018-07-31 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Tech stocks rebounded slightly while bank stocks lost some traction Tuesday. After a few good days for banks and a tough few days for tech, that's not much of a surprise.
What could really shake things up though? Apple (NASDAQ: AAPL ), which reports after t... | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. 10 Best Tech Stocks to Buy on T... | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market Ne... | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market Ne... | Top Stock Trades for Tomorrow #4: AbbVie (ABBV) Shares of AbbVie (NYSE: ABBV ) are making a pretty standard move, with $86 support and downtrend resistance both in play. Now that ABBV is putting in a series of higher lows, we would ordinarily look for a push through downtrend resistance. InvestorPlace - Stock Market Ne... |
25,390 | 2018-07-31 00:00:00 UTC | Seattle Genetics' Latest Approval Is the Best Yet | ABBV | https://www.nasdaq.com/articles/seattle-genetics-latest-approval-best-yet-2018-07-31 | null | null | Seattle Genetics (NASDAQ: SGEN) saw sales of its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV Hodgkin lymphoma, which was granted in the first quarter .
Seattle Genetics results: The raw numbers
... | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . The biotech posted a net income during the quarter, but that was solely due to a $105 million increase in values of stock holdings, primarily in Immunomedics (NASDAQ: IMMU) . Turning to the pipeline, enfortumab vedotin,... | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Seattle Genetics results: The raw numbers Data source: Seattle Genetics. The frontline Hodgkin lymphoma data was submitted to Health Canada, putting an expected approval in the first half of 2019. | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Seattle Genetics (NASDAQ: SGEN) saw sales of its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV ... | This quarter included payments from Genmab , GlaxoSmithKline (NYSE: GSK) , and AbbVie (NYSE: ABBV) . Sales of Adcetris increased 65% year over year during the first full quarter that the drug was approved as a frontline treatment for Hodgkin lymphoma. Royalty revenue, which is mostly from sales of Adcetris outside the ... |
25,391 | 2018-07-30 00:00:00 UTC | AbbVie's Stock Is Incredibly Cheap | ABBV | https://www.nasdaq.com/articles/abbvies-stock-incredibly-cheap-2018-07-30 | null | null | At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest valuations among either big pharma or Dividend Aristocrat stocks right now. In fact, Celgene Corporation and Teva Pharmaceutical Industries Ltd. are the only large-cap drug manufacturers trading at lower multiples than AbbVie. W... | Despite the biotech's $5.8 billion misstep with the solid tumor medicine Rova-T earlier this year, AbbVie has still managed to build out an impressive array of future growth products that are starting to come online right now. At around 10-times forward-looking earnings, AbbVie (NYSE: ABBV) sports one of the cheapest v... | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. The take away is that AbbVie should be able to keep delivering healthy levels of revenue growth for years, thanks both to Humira's built-in competitive moat as a biologically ba... | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. Despite the biotech's $5.8 billion misstep with the solid tumor medicine Rova-T earlier this year, AbbVie has still managed to build out an impressive array of future growth pro... | AbbVie's management team was thus tasked with building a clinical pipeline capable of producing revenue growth even as Humira went off patent. Therefore, AbbVie should not only have little problem offsetting Humira's decline, but the drugmaker should be able to continue generating top notch revenue growth well into the... |
25,392 | 2018-07-30 00:00:00 UTC | Worried About AbbVie? 5 Things the Big Pharma's CEO Just Said You'll Want to Know | ABBV | https://www.nasdaq.com/articles/worried-about-abbvie-5-things-big-pharmas-ceo-just-said-youll-want-know-2018-07-30 | null | null | There's been considerable negativity in the investment community about AbbVie (NYSE: ABBV) lately. Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates.
This negativity was evident last week when Abb... | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. However, AbbVie CFO Bill Chase said the company expects Q3 revenue for its HCV franchise, which primarily consists of Mavyret sales, to drop to $... | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. Gonzalez pointed out that AbbVie will deliver 40% earnings per share (EPS) growth this year with 25% operational EPS growth excluding tax benefit... | Two other megablockbuster assets right now AbbVie has come a long way from just being "the Humira company," according to Gonzalez. While the company expects a relatively slow ramp-up, with sales of less than $50 million this year, Gonzalez said that AbbVie got "everything that we hoped for in the label" for the drug an... | Noted short-seller Andrew Left with Citron Research recently called AbbVie "the next great short" because of potential changes coming related to biosimilars and drug rebates. Gonzalez stated that AbbVie has "never once disappointed investors" and that in most quarters, like it did in its recent Q2 results, the company ... |
25,393 | 2018-07-29 00:00:00 UTC | 3 Cheap Big Pharma Dividend Stocks That You Can Buy Now and Hold for Years | ABBV | https://www.nasdaq.com/articles/3-cheap-big-pharma-dividend-stocks-you-can-buy-now-and-hold-years-2018-07-29 | null | null | One of the greatest enemies of investors is trading too frequently. Jumping in and out of stocks too often dramatically reduces returns over the long run. That's why it pays to find stocks that you can buy and hold onto for years.
Stocks that meet three criteria often make the best long-term picks. First, their valuati... | Market research firm EvaluatePharma ranks AbbVie's pipeline as the second-best in the industry , with potential blockbuster drugs including risankizumab and upadacitinib likely on the way. I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pf... | I think three big pharma stocks currently meet all of these criteria: AbbVie (NYSE: ABBV) , Gilead Sciences (NASDAQ: GILD) , and Pfizer (NYSE: PFE) . Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. AbbVie AbbVie stock is definitely cheap right now. | Only for long-term investors If you're looking for stocks that will skyrocket in just a few months, AbbVie, Gilead Sciences, and Pfizer probably aren't for you. Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. I think three big pharma stocks currently meet all of these criteria... | Only for long-term investors If you're looking for stocks that will skyrocket in just a few months, AbbVie, Gilead Sciences, and Pfizer probably aren't for you. Investors who buy and hold AbbVie, Gilead, and Pfizer stocks should win over the long run. I think three big pharma stocks currently meet all of these criteria... |
25,394 | 2018-07-27 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 63.6% Follow-Through Indicator, 4.7% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-636-follow-through-indicator-47-sensitive-2018-07-27 | null | null | Expected Earnings Release: 07/27/2018, Premarket
Avg. Extended-Hours Dollar Volume: $8,119,533
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings an... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of... | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time adde... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 85.7% Average next regular session additional gain: 3.4% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 85.7% of... | Extended-Hours Dollar Volume: $8,119,533 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of significant va... |
25,395 | 2018-07-27 00:00:00 UTC | AbbVie (ABBV) Tops Q2 Earnings and Revenues, View Up | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q2-earnings-and-revenues-view-up-2018-07-27 | null | null | North Chicago, IL-based AbbVie Inc.ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, activ... | AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. North Chicago, IL-based AbbVie Inc.ABB... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's second-quarter earnings came in at $2.00 per share, beating the Zacks Consensus Estimate of $1.98. Revenues: AbbVie posted revenues of $8.28 billion, which marginally beat the Zacks Consensus Estimate of $8.27 billi... |
25,396 | 2018-07-27 00:00:00 UTC | AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q2-earnings-beat-estimates-2018-view-up-2018-07-27 | null | null | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Moreover, the company raised its expectations for 2018 bottom line. However, shares fell almost 1.8% in pre-market trading .
Shares of AbbVie have declined 2.9% in a year's time against the industry... | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have declined 2.9% in a year's time against the industry 's 1.2% rise. AbbVie logged $157 million of international profit sharing with Johnson & Johnson JNJ . | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (... | AbbVie Inc.ABBV posted impressive results for the second quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have declined 2.9% in a year's time against the industry 's 1.2% rise. AbbVie logged $157 million of international profit sharing with Johnson & Johnson JNJ . |
25,397 | 2018-07-27 00:00:00 UTC | Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales | ABBV | https://www.nasdaq.com/articles/roche-rhhby-1h18-revenues-up-y-y-on-solid-new-drug-sales-2018-07-27 | null | null | Swiss pharma giant Roche Holding AGRHHBY reported solid sales growth in the first half of 2018 as well as in the second quarter, propelled by growth in sales of new drugs. The company also upped its annual guidance for the second time in 2018.
The strong performance should boost investors' sentiment. Roche's stock has ... | Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS):... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Roche and partner AbbVie ABBV also won the FDA appro... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Roche and partner AbbVie ABBV also won the FDA appro... | Roche and partner AbbVie ABBV also won the FDA approval for Venclexta in combination with Rituxan/MabThera for the treatment of patients suffering from chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS):... |
25,398 | 2018-07-27 00:00:00 UTC | 2 Reasons the Market Frowned After AbbVie's Blowout Q2 -- and 1 Reason It Should Be Excited | ABBV | https://www.nasdaq.com/articles/2-reasons-market-frowned-after-abbvies-blowout-q2-and-1-reason-it-should-be-excited-2018 | null | null | AbbVie (NYSE: ABBV) did it again. The big drugmaker posted fantastic numbers in its first-quarter results reported in April. AbbVie announced more great results with its second-quarter earnings update on Friday.
Net revenue jumped 19% year over year to $8.28 billion. Adjusted earnings per share (EPS) soared nearly 41% ... | The drug, along with another candidate, upadacitinib, is an important component of AbbVie's strategy to maintain its dominance in the immunology market even after Humira loses patent protection. AbbVie should have plenty of time for its current drugs and pipeline candidates to generate growth and offset any decline in ... | AbbVie (NYSE: ABBV) did it again. AbbVie announced more great results with its second-quarter earnings update on Friday. AbbVie even boosted its full-year 2018 adjusted EPS guidance from between $7.66 and $7.76 to between $7.76 and $7.86. | Slowing growth for Humira The first thing investors look for in AbbVie's quarterly results after the top-line and bottom-line numbers is Humira's sales figure. Stabilization for Gilead's HCV drug franchise, however, also means that AbbVie's HCV drug sales will also stabilize. AbbVie should have plenty of time for its c... | Slowing growth for Humira The first thing investors look for in AbbVie's quarterly results after the top-line and bottom-line numbers is Humira's sales figure. AbbVie (NYSE: ABBV) did it again. AbbVie announced more great results with its second-quarter earnings update on Friday. |
25,399 | 2018-07-27 00:00:00 UTC | Health Care Sector Update for 07/27/2018: NBRV,ABBV,TNXP | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-07272018-nbrvabbvtnxp-2018-07-27 | null | null | Top Health Care Stocks
JNJ +1.39%
PFE +0.58%
ABT -0.67%
MRK -1.08%
AMGN -0.69%
Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were down nearly 0.9% as a group while the Nasdaq Biotechnology in... | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Among health care stocks moving on news: - Nabriva Therapeutics AG ( NBRV ) dropped to a record low on Friday, sinking ... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital... | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Care Index in recent trad... | In other sector news: - AbbVie ( ABBV ) was down almost 5% lower Friday afternoon after AbbVie said it earned an adjusted $2.00 per share on $8.28 billion in revenue, topping the Capital IQ consensus. Top Health Care Stocks Health care stocks were declining Friday, including a nearly 0.5% retreat for the NYSE Health Ca... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.